Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

259517 items
11:41 AM, Oct 19, 2018  |  BioCentury | Finance

Warp Drive’s winding road to Revolution

After winding through nearly seven years of shifting strategies and a delayed entry into the clinic, Warp Drive Bio Inc. has opted for a takeout by fellow Third Rock Ventures portfolio company Revolution Medicines Inc....
11:37 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

AbbVie, Morphic partner on antifibrotic integrins

AbbVie Inc. (NYSE:ABBV) agreed to pay Morphic Therapeutic (Waltham, Mass.) $100 million up front for exclusive options to license antifibrotic integrins to block transforming growth factor β (TGFβ) activation via multiple undisclosed targets. Morphic is responsible...
11:34 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Apellis pauses Phase III trials after single lot of APL-2 causes inflammation

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) voluntarily paused dosing in Phase III trials of intravitreal APL-2 to treat geographic atrophy due to eight reported cases of non-infectious inflammation in patients treated from a single manufacturing lot of...
11:33 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

SQZ, Roche expand deal to jointly develop cancer cell therapies

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy...
11:27 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Other News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
11:26 AM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Other Financial News

Taiho Ventures increases investment pool to $300M

Taiho Ventures LLC increased its investment pool to $300 million from $50 million. The firm said it will focus the additional funds on oncology startups with drug discovery capabilities or unique platform technologies. Taiho Pharmaceutical Co....
11:26 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Other News

WideTrial seeks to increase expanded access programs by helping companies recover costs

FDA has authorized WideTrial Inc. (San Francisco, Calif.) to charge payment for an expanded access program for critical limb ischemia (CLI) candidate PLX-PAD from Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) under a cost recovery program....
11:25 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Regulatory

FDA panel votes in favor of AcelRx's pain candidate

FDA's Anesthetic and Analgesic Drug Products Advisory Committee voted 10-3 that the benefit-risk profile of Dsuvia sufentanil sublingual tablet (ARX-04) from AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) supports its approval to manage moderate to severe acute pain...
11:21 AM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Iovance closes $252M follow-on for Phase II trials

Iovance Biotherapeutics (NASDAQ:IOVA) closed a $252.2 million follow-on to fund five ongoing company-sponsored Phase II trials of its tumor infiltrating lymphocyte (TIL) cell therapies and prepare for potential launch of its lead TIL product. Iovance...
11:17 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Proteostasis' doublet CF therapy improves lung function in Phase I

Proteostasis Therapeutics Inc. (NASDAQ:PTI) reported that its doublet cystic fibrosis therapy improved percent predicted forced expiratory volume in 1 second (ppFEV1) and sweat chloride levels in a Phase I trial. The doublet therapy comprised CF...

Pages